Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Kainomyx
Deal Size : Undisclosed
Deal Type : Agreement
Dr. Reddy's, Aurigene, Kainomyx Partner For Affordable Anti-Malarial Drug
Details : Kainomyx has agreed to lead the technical strategy and associated aspects for drug discovery and clinical phases, Aurigene has agreed to focus on developing cost-effective and scalable drug chemistry.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
August 20, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Kainomyx
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Fermenta Biotech Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Fermenta Biotech will exclusively license its biocatalytic technology for synthesis of Molnupiravir (Molflu) and supply its enzyme Candida Antarctica B Lipase (CAL B) to Aurigene. Molnupiravir API manufactured by Aurigene will be utilised by Dr Reddy’s...
Brand Name : Molflu
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 21, 2022
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Fermenta Biotech Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : PENAO,Sirolimus
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : PENAO Pty Ltd
Deal Size : Undisclosed
Deal Type : Agreement
Beroni Initiates Manufacture of its Novel, Potential Anti-Cancer Drug PENAO
Details : This next-generation adenine nucleotide translocase (ANT) inhibitor, PENAO, was shown to be safe and well-tolerated in a phase I clinical trial conducted in Australia where encouraging efficacy data was observed.
Brand Name : PENAO
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 18, 2021
Lead Product(s) : PENAO,Sirolimus
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : PENAO Pty Ltd
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Zoliflodacin,Ceftriaxone,Azithromycin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : The Global Antibiotic Research and Development Partnership
Deal Size : Undisclosed
Deal Type : Agreement
Details : Through this MOU, the parties will seek to collaborate on efforts to determine market potential for zoliflodacin, therapeutic value to patients and explore possibilities to enter into future manufacturing and supply agreements.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 17, 2020
Lead Product(s) : Zoliflodacin,Ceftriaxone,Azithromycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : The Global Antibiotic Research and Development Partnership
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
KEY SERVICES
Reset All
Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.